First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial

Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer

Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste et al. · New England Journal of Medicine · 2017 · 5.3K citations · Full text

Medicine, Oncology, Pharmacology +16

Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC

Suresh S. Ramalingam, Johan Vansteenkiste, David Planchard et al. · New England Journal of Medicine · 2019 · 2.8K citations · Full text

Medicine, Oncology, Pharmacology +17

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

Yi‐Long Wu, Ying Cheng, Xiangdong Zhou et al. · The Lancet Oncology · 2017 · 1.2K citations

Medicine, Oncology, Pharmacology +12

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

Keunchil Park, Eng-Huat Tan, Kenneth J. O’Byrne et al. · The Lancet Oncology · 2016 · 1.2K citations

Medicine, Oncology, Pharmacology +11

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated <i>EGFR</i>-Mutated Advanced Non–Small-Cell Lung Cancer

Thanyanan Reungwetwattana, Kazuhiko Nakagawa, Byoung Chul Cho et al. · Journal of Clinical Oncology · 2018 · 789 citations · Full text

Medicine, Oncology, Pharmacology +17